Suggestions
Dr. Shelby
Compound
Shelby Newsad is an investor at Compound, a venture capital firm based in New York City, focusing on biology and healthcare investments.4 She holds a PhD in Plant Sciences from the University of Cambridge and has a diverse background in scientific research.15
Career
- Current Role: Partner at Compound since July 20225
- Investment Focus: Biology and healthcare, with over 20 active theses in these sectors4
- Investment Range: $100K to $3M, primarily in Seed and Series A rounds2
Education
- PhD in Plant Sciences, University of Cambridge (2018-2022)5
- MPhil in Bioscience Enterprise, University of Cambridge (2017-2018)5
- Bachelor's Degree in Biochemistry with Engineering Sciences Minor, The Ohio State University (2012-2016)5
Research Experience
- Plant Sciences (PhD project at University of Cambridge)1
- Neuroscience (National Institutes of Health)15
- Drug Discovery (Helmholtz Institute)15
Previous Roles
- Analyst at Hummingbird Ventures (2021-2022)5
- Team Lead for Due Diligence Projects at Start Codon (2020-2021)5
- Summer Intern at Ahren Innovation Capital (2020)5
Shelby is known for her network growth, writing skills, and rapid rise in the venture capital industry.3 She is committed to facilitating step-change technologies in bio and health sectors and is valued for her deep technical understanding and ability to be a helpful thought partner for companies in these fields.4
Highlights
Some areas are creativity constrained (like AI) where there’s a sea of me-too companies. On the flipside, there’s many spaces that are innovation constrained like bio surveillance where you see different business model around the same tech.
I think part of building companies in highly technical areas is understanding what you field needs most and leaning into that maximally.
Wondering if anyone else is watching $PALI this week?
Big readout was Sept 25 showing remission in a small subset of patients, clinical response in all patients (though only 5), seeming selective bio activity in the colon given the prodrug (which is degraded by enzymes from bacteria only active in colon; b-glucuronidase)
Interesting bc an autoimmune drug but relies on understanding gut microbiome for selective efficacy that prevents toxicity.
This makes means that drug efficacy is dependent on not being on antibiotics. Also different diets confer lower bacterial species that make the enzyme meaning there could be spotty efficacy in broad population or commensurate diet changes.
Readout on 1/23 is on lymphocyte counts in colon vs plasma so not a massive bump. Still tracking. Open to thoughts!